Nuvation Bio reported its Q1 2024 financial results, highlighting the acquisition of AnHeart Therapeutics and the treatment of the first patient in a Phase 1/2 study of NUV-1511. The company's cash, cash equivalents, and marketable securities totaled $597.0 million as of March 31, 2024. The net loss for the quarter was $14.8 million, or $(0.07) per share.
Completed the acquisition of AnHeart Therapeutics, transforming Nuvation Bio into a late-stage, global oncology company.
Treated the first patient in a Phase 1/2 study of NUV-1511, the company’s first drug-drug conjugate (DDC).
Cash, cash equivalents, and marketable securities of $597.0 million as of March 31, 2024.
Updated data from the pivotal Phase 2 TRUST-I clinical study of taletrectinib will be presented at the 2024 ASCO Annual Meeting.
Nuvation Bio is scaling its organization to potentially become a commercial organization by the end of 2025, while continuing to advance multiple internal programs in various stages of preclinical and clinical development.
Analyze how earnings announcements historically affect stock price performance